

# C-reactive protein and lactate dehydrogenase as prognostic indicators in COVID-2019 outpatients

Keiko Suzuki<sup>1</sup>, Takaya Ichikawa<sup>2</sup>, Satoshi Suzuki<sup>1</sup>, Yoko Tanino<sup>3</sup>, Yasutaka Kakinoki<sup>2</sup>

<sup>1</sup> Department of general internal medicine, Asahikawa City Hospital, Asahikawa, Japan

<sup>2</sup> Department of hematology, Asahikawa City Hospital, Asahikawa, Japan

<sup>3</sup> Department of respiratory medicine, Asahikawa City Hospital, Asahikawa, Japan

Corresponding Author:

Keiko Suzuki<sup>1</sup>

Kinseichou-1choume, Asahikawa, Hokkaido, 070-8610, Japan

Email address: [kii\\_suzu@yahoo.co.jp](mailto:kii_suzu@yahoo.co.jp)

## Abstract

**Background.** It is critical for clinicians seeing outpatients with coronavirus disease 2019 (COVID-19) to identify those who will require oxygen therapy after the hospital visit. Although studies on biomarkers predicting mortality or ventilator requirement in hospitalized patients with COVID-19 have been conducted, research on biomarkers predicting the need for oxygen therapy in outpatients is sparse.

**Methods.** Patients with COVID-19 who visited Asahikawa City Hospital on an outpatient basis were included in the study. In total, 287 new outpatients visited between April 2021 and September 2021, and 142 underwent blood testing. All blood tests were performed before any treatments for COVID-19 were started. Demographic information, laboratory data, and clinical treatment information were extracted from the electronic medical records. Risk factors associated with oxygen therapy were explored.

**Results.** In total, 40 of 142 patients who underwent blood testing required oxygen therapy within 7 days after blood samples were taken, and all other patients recovered without oxygen therapy. C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels were significantly higher in patients who required oxygen therapy, and their cutoffs were 36 mg/L (sensitivity, 0.802; specificity, 0.725) and 267 U/L (sensitivity, 0.713; specificity, 0.750), respectively. Multivariate logistic regression identified age, body mass index, CRP  $\geq$  36 mg/L, and LDH  $\geq$  267 U/L as significant risk factors for oxygen therapy requirement. This study suggests that elevated CRP and LDH levels are independent risk factors for oxygen therapy in outpatients with COVID-19. Further confirmatory studies are needed.

## Introduction

Biomarkers can play a key role in decision making by physicians in daily practice for patients with coronavirus disease 2019 (COVID-19) (Tabassum et al., 2021). It is important for clinicians to identify patients requiring hospitalization. To ensure the efficient allocation of

42 medical resources, patients who require oxygen therapy should be prioritized for hospitalization  
43 (Yamada et al., 2021).

44 Vahey et al. reported that chronic hypoxemic respiratory failure with a requirement for  
45 oxygen supplementation, opioid use, metabolic syndrome, obesity, age  $\geq 65$  years, hypertension,  
46 arrhythmia, and male sex were significantly associated with the risk of hospitalization among  
47 patients with COVID-19 (Vahey et al., 2021). Yamada et al. created a clinical score for  
48 evaluating the need for hospitalization based on age, sex (male), BMI, medical history, and  
49 symptoms (Yamada et al., 2021). Although such information is helpful, it is sometimes difficult  
50 to precisely predict the prognosis of COVID-19 in daily practice without biomarkers.

51 Biomarkers of inflammation and coagulopathy can aid in identifying patients hospitalized  
52 with COVID-19 who are at risk for clinical deterioration (Anyan et al., 2020). Poudel et al.  
53 reported that the d-dimer level on admission is an accurate biomarker predicting mortality in  
54 patients with COVID-19 (1.5  $\mu\text{g}/\text{mL}$  is the optimal cutoff) (Poudel et al., 2021). Li et al. reported  
55 that an elevated lactate dehydrogenase (LDH) level at admission is an independent risk factor for  
56 the severity and mortality of COVID-19 (Li et al., 2020). Rahman et al. reported that C-reactive  
57 protein (CRP), d-dimer, and ferritin levels at hospital admission represent simple assessment  
58 factors for COVID-19 severity (Rahman et al., 2021). The neutrophil-to-lymphocyte ratio (NLR)  
59 is also mentioned to be a strong predictor of the prognosis for patients with severe COVID-19  
60 using a cutoff of 4.4 (Kilercik et al., 2021). Procalcitonin may also be useful for predicting  
61 prognosis (Hu et al., 2021). Decreased albumin and globulin levels were independent factors  
62 related to oxygen therapy in patients younger than 65 years who were admitted for COVID-19  
63 (Ni et al., 2021). However, these studies used the data of patients who had been admitted to the  
64 hospital. Because the biomarkers' level change during the stages of COVID-19, there appears to  
65 be no consensus regarding the biomarkers predictive of prognosis among outpatients who require  
66 admission and oxygen therapy.

67 Therefore, this study analyzed the data of outpatients to identify the biomarkers  
68 predictive of the need for oxygen therapy in patients with COVID-19. Additionally, we  
69 discussed the optimal cutoffs of the predictive biomarkers.

70

71

72

73

## 74 **Materials & Methods**

### 75 **Study design and participants**

76 From April 2021 to September 2021, outpatients newly diagnosed with COVID-19 who  
77 visited Asahikawa City Hospital as new patients were enrolled in the study. All patients were  
78 diagnosed by polymerase chain reaction for severe acute respiratory syndrome coronavirus 2  
79 (SARS-CoV-2) genes and/or antigen quantitation testing.

80 The endpoint of this study was the requirement for oxygen therapy, which was definitely  
81 administered to patients with percutaneous oxygen saturation levels of  $\leq 92\%$ .

## 82 **Ethics**

83 This study was approved by the ethics committee of Asahikawa City Hospital and  
84 conducted in accordance with the ethical standards set forth in the Declaration of Helsinki  
85 (1983). The opt-out method was used to obtain patient consent in this study.

## 86 **Data collection**

87 All demographic, clinical, and outcome data were retrospectively extracted from the  
88 Asahikawa City Hospital record files. The demographic characteristics of the patients (age, sex,  
89 body mass index [BMI]); white blood cell count (WBC); NLR; LDH, aspartate aminotransferase  
90 (AST), alanine aminotransferase (ALT), d-dimer, and ferritin levels; comorbidities, and clinical  
91 courses were recorded. The time from the onset of symptoms to blood sampling was also  
92 recorded. All blood samples were taken before patients received any treatment for COVID-19.

## 93 **Statistical analysis**

94 Continuous data were analyzed using the Mann–Whitney U test and presented as the  
95 mean (interquartile range). For categorical variables, Fisher’s exact test or the chi-squared test  
96 was used, as appropriate. The receiver operating characteristic (ROC) curve, sensitivity,  
97 specificity, and area under the curve (AUC) were measured to evaluate the levels of laboratory  
98 indicators predicting the need for oxygen therapy. We considered that the best cutoff was near  
99 the shoulder of the ROC curve because as the sensitivity is progressively increased, there is little  
100 or no loss in specificity until extremely high levels of sensitivity are achieved. The cumulative  
101 probability that patients with COVID-19 would not require oxygen therapy was described via  
102 Kaplan–Meier analysis and analyzed using log-rank test. Patients who required oxygen therapy  
103 started this treatment within 7 days after blood sampling, and thus, the analysis was performed  
104 within 8 days (follow-up time) after blood sampling.

105 Multivariate logistic analysis was used to exploit the risk factors for oxygen therapy.  $P <$   
106  $0.05$  was considered statistically significant. Statistical analysis was performed using BellCurve  
107 for Excel by Social Survey Research Information Co. Ltd and EZR by Saitama Medical Center,  
108 Jichi Medical University, Saitama, Japan, which is a 120 graphical user interface for R (The R  
109 Foundation for Statistical Computing, Vienna, 121 Austria) (Kanda et al., 2013).

110

## 111 **Results**

### 112 **Characteristics**

113 In total, 287 outpatients who visited Asahikawa City Hospital for the first time were  
114 eligible for the study. We excluded five patients who were admitted to other hospitals after they  
115 visited our hospital because the clinical course data were missing.

116 We divided the patients into two groups according to the need for oxygen therapy. S1  
117 Table presents the characteristics of the 282 outpatients included in the study. Among the  
118 included patients, 142 received blood tests before any treatment for COVID-19 was started. All  
119 blood samples were collected at the outpatient setting. In total, 138 patient samples were  
120 collected at the first visit to our hospital’s outpatient unit. Four patient samples were collected at  
121 the second or third visit. Table 1 presents the characteristics of 142 patients who underwent

122 blood testing. Details of their comorbidities are presented in S2 Table. Forty patients required  
 123 oxygen therapy, and the remaining patients recovered without oxygen therapy. The median  
 124 patient age was 55 (45.5–72.25) years among those requiring oxygen therapy, versus 44.5 (34.3–  
 125 52.8) years among those who did not require oxygen therapy ( $P < 0.001$ ). The proportions of  
 126 males among patients who did and did not receive oxygen therapy were 57.8% and 57.5% ( $P >$   
 127 0.999), respectively. No significant difference was found in BMI, smoking history, receipt of  
 128 SARS-CoV-2 vaccines, comorbidities, and the time from onset between the patients who did and  
 129 did not require oxygen therapy. The ROC curves of BMI and age distinguishing the need for  
 130 oxygen therapy are presented in Fig 1, and the AUCs of age and BMI were 0.699 (0.603–0.795)  
 131 and 0.604 (0.496–0.713), respectively. The optimal cutoffs of BMI and age were 25.2 kg/m<sup>2</sup> and  
 132 52 years, respectively. The sensitivity and specificity of BMI were 0.611 and 0.619, respectively,  
 133 and those of age were 0.625 and 0.922, respectively.

134

135 **Table 1. Characteristics of 142 outpatients who underwent blood testing**


	No oxygen therapy (n = 102)	Oxygen therapy (n = 40)	P
<b>Demographics</b>			
Male (%)	59 (57.8%)	23 (57.5%)	1
Age (years), median (IQR)	44.5 (34.3–52.8)	55 (45.5–72.25)	<0.001*
BMI, median (IQR) (missing: 28.7%)	23.9 (21.5–27.3)	25.7 (23.1–28.6)	0.071
Smoking, yes (%) (missing: 33.7%)	46 (47.4%)	20 (50%)	0.852
SARS-CoV-2 vaccines, yes (%)	4 (3.9%)	3 (7.5%)	0.402
Comorbidities (%)	40 (39.2%)	21 (52.5%)	0.211
Time from onset (days), median (IQR)	5 (3–7)	6 (3–7.5)	0.577
<b>Laboratory findings</b>			
WBC (/μL), mean (IQR)	4550 (3817.5–5460)	5315 (4157.5–9920)	0.049*
Neutrophil-to-lymphocyte ratio, mean (IQR)	2.81 (1.94–4.64)	4.74 (3.87–7.39)	<0.001*
AST (U/L), mean (IQR)	28.5 (22.0–35.75)	39.0 (28.5–56.5)	<0.001*
ALT (U/L), mean (IQR)	23.0 (15.25–44.5)	25.5 (17.0–39.25)	0.462
LDH (U/L), mean (IQR) (missing: 0.7%)	221 (188–986)	313 (264–415)	<0.001*

Ferritin (ng/mL), mean (IQR) (missing: 14.7%)	249.7 (105.5–450.4)	465.8 (214.6–847.0)	0.004*
D-dimer (µg/mL), mean (IQR) (missing: 14.7%)	0.3 (0.20–0.78)	1.0 (0.55–1.20)	<0.001*
CRP (mg/L), mean (IQR)	1.96 (0.66–3.21)	6.29 (3.16–9.75)	<0.001*

136 \*Significant at P < 0.05

137

138 **Figure 1. ROC curves of BMI and age distinguishing the need for oxygen therapy**



139


140 **Laboratory findings**

141 In patients requiring oxygen therapy, higher WBC (5315/µL [4157.5–9920] vs. 4550/µL  
 142 [3817.5–5460]/µL, P = 0.049), higher NLR (4.74 [3.87–7.39] vs. 2.81 [1.94–4.64], P < 0.001),  
 143 higher LDH (313 U/L [264–415] vs. 221 U/L [188–986], P < 0.001), higher CRP (62.9 mg/L  
 144 [31.6–97.5] vs. 19.6 mg/L [6.6–32.1], P < 0.001), higher ferritin (465.8 ng/mL [214.6–847.0] vs.  
 145 249.7 ng/mL [105.5–450.4], P = 0.004), and higher d-dimer (1.0 µg/mL [0.55–1.20] vs. 0.3  
 146 µg/mL [0.20–0.78], P < 0.001) were found. ALT levels did not differ between the groups (39.0  
 147 U/L [28.55–56.5] vs. 28.5 U/L [22.0–35.75], P = 0.462). We selected WBC, NLR, CRP, AST,  
 148 and LDH as potential biomarkers predicting the need for oxygen therapy, whereas ferritin and d-  
 149 dimer were excluded because these data were missing for 14.7% of patients.

150 The ROC curves of WBC, NLR, CRP, AST, and LDH in distinguishing the need for  
 151 oxygen therapy are presented in Fig 2. Table 2 presents the AUC, P-value, cutoff, sensitivity, and  
 152 specificity of each variable. The AUCs of WBC, NLR, CRP, AST, and LDH for predicting the  
 153 need for oxygen therapy were 0.604, 0.730, 0.799, 0.716, and 0.774, respectively. The optimal  
 154 cutoffs of WBC, NLR, CRP, AST, and LDH were 5270/µL, 3.546, 36 mg/L, 35 U/mL, and 267  
 155 U/mL, respectively. The respective sensitivity and specificity of these variables were as follows:  
 156 WBC, 0.683 and 0.525; NLR, 0.644 and 0.825; CRP, 0.802 and 0.725; AST, 0.723 and 0.675;  
 157 and LDH, 0.713 and 0.750. There was no significant difference in AUC among CRP, LDH,  
 158 NLR, and AST, whereas that of WBC was significantly lower than those of the other variables (P

159 < 0.05). We selected CRP and LDH for further analysis because they had higher AUCs and they  
 160 are routinely used in daily practice.

161  
 162 **Figure 2. ROC curves of WBC, NLR, CRP, AST, and LDH in distinguishing the need for**  
 163 **oxygen therapy**




164  
 165 **Table 2. The AUC (95% confidence interval [CI]), P-value, cutoff, sensitivity, and**  
 166 **specificity of WBC, NLR, CRP, AST, and LDH in predicting the need for oxygen therapy**

	AUC	95% CI	P-value	Cutoff	Sensitivity	Specificity
WBC	0.604	0.497–0.711	0.056	5270/ $\mu$ L	0.683	0.525
NLR	0.730	0.635–0.825	<0.001*	3.546	0.644	0.825
CRP	0.799	0.711–0.886	<0.001*	36 mg/L	0.802	0.725
AST	0.716	0.618–0.813	<0.001*	35 U/mL	0.723	0.675
LDH	0.7743	0.689–0.856	<0.001*	267 U/mL	0.713	0.750


167  
 168 All patients in the oxygen therapy group started therapy within 7 days of blood testing.  
 169 The Kaplan–Meier distributions revealed a significant difference in the rates of oxygen therapy  
 170 between low (<35 mg/L) and high ( $\geq$ 35 mg/L) CRP levels (log-rank  $P < 0.001$ , Fig. 3) and  
 171 between low (<267 U/L) and high ( $\geq$ 267 U/L) LDH levels (log-rank  $P < 0.001^*$ , Fig. 4).

172  
 173  
 174  
 175  
 176  
 177  
 178

179 **Figure 3. Kaplan–Meier estimates of the cumulative probability that patients with COVID-**  
180 **19 would require oxygen therapy according to plasma CRP < 36 mg/L vs. CRP ≥ 36 mg/L**



181 **Figure 4. Kaplan–Meier estimates of the cumulative probability that patients with COVID-**  
182 **19 would require oxygen therapy according to plasma LDH < 267 U/L vs. LDH ≥ 267 U/L**




185  
186 The results of multivariate logistic regression analysis for predicting the need for oxygen  
187 therapy according to age, BMI, CRP ≥ 36 mg/L, LDH ≥ 267 U/mL, and comorbidities are  
188 presented in Fig 5. Age, BMI, CRP, and LDH were predictive of a significantly higher need for  
189 oxygen therapy with odds ratios (95% CIs) of 1.06 (1.02–1.10), 1.15 (1.02–1.29), 7.83 (2.45–  
190 25.1), and 3.9 (1.14–13.3), respectively (Fig 5).

191  
192  
193  
194  
195  
196  
197  
198

199 **Fig 5. Odds ratios and 95% CIs of age, BMI, CRP, and LDH (multivariate logistic**  
200 **regression analysis)**

201



202

## 203 Discussion

204 This study aimed to identify useful laboratory findings predicting the need for oxygen  
205 therapy among outpatients with COVID-19. In multivariate analysis, CRP  $\geq 36$  mg/L, and LDH  
206  $\geq 267$  U/L are independent risk factors for oxygen therapy. CRP and LDH are widely used and  
207 inexpensive to measure. Our findings will help physicians during the management of COVID-19  
208 by indicating the need for frequent follow-up or therapies to avoid poor prognoses.

209 Excessive inflammation is considered the main cause of critical illness and death in  
210 patients with COVID-19 (Luan et al., 2021). CRP levels are obviously increased in the presence  
211 of acute inflammation, and they might normalize after inflammation subsides (Luan et al., 2021).  
212 CRP levels in the early stage of COVID-19 have been reported to be positively correlated with  
213 the presence of lung lesions (Wang et al., 2020). During the process of COVID-19 pneumonia, a  
214 cytokine response storm can be triggered, which is associated with high mortality in COVID-19  
215 (Azar et al., 2020). Because the CRP level varies by stage of inflammation, the CRP cutoff  
216 predicting severity should change according to the stage. CRP  $\geq 110$  mg/L is associated with  
217 moderate-to-severe acute respiratory distress syndrome in patients with COVID-19 (Poggiali et  
218 al., 2020). Patients with CRP  $> 64.75$  mg/L on admission were more likely to have severe  
219 complications of COVID-19 (Sadeghi-Haddad-Zavareh et al., 2021). Stringer et al. reported that  
220 a CRP cutoff of  $\geq 40$  mg/L on admission was a good indicator of mortality in patients with  
221 COVID-19 (Stringer et al., 2021). These previous studies focused on CRP levels at admission to  
222 predict disease severity. Our study therefore provides useful information by suggesting a CRP  
223 cutoff of  $\geq 36$  mg/L for identifying outpatients who will require oxygen therapy.

224 LDH is an inflammatory marker that may serve as a common indicator of acute or severe  
225 tissue damage (Sepulveda et al., 2019). Cytokine-mediated lung tissue damage, which is a  
226 primary feature of COVID-19, may be responsible for the elevated release of LDH (Martinez-  
227 Outschoorn et al., 2011). LDH  $\geq 450$  U/L on hospitalization was associated with moderate-to-



228 severe acute respiratory distress syndrome in patients with COVID-19 (Poggiali et al., 2020). Li  
229 et al. reported that LDH levels of  $\geq 359.5$  and  $\geq 277$  U/L at admission was associated with death  
230 and severe COVID-19, respectively (Li et al., 2020). Although this report used the serum LDH  
231 level at admission, the result was similar to those of our study, which suggested that LDH  $\geq 267$   
232 U/L in outpatients with COVID-19 was predictive of the need for oxygen therapy. Additionally,  
233 in multivariate analysis, serum LDH  $\geq 267$  U/mL remained an independent risk factor for  
234 oxygen therapy in our study, in line with the results of Li et al.

235 Our findings suggest that both CRP  $\geq 36$  mg/L and LDH  $\geq 267$  U/L are useful for  
236 identifying patients who will require oxygen support in the near future, and there was no  
237 statistical difference in the AUC between these variables. We used patients' samples obtained at  
238 their visits, and the samples were obtained a median of 5 days after symptom onset in the  
239 nonoxygen therapy group and a median of 6 days in the oxygen therapy group. Meanwhile,  
240 patients who needed oxygen support started within 7 days of blood sampling. Because LDH and  
241 CRP levels exhibit dynamic changes during the progression of COVID-19, the interval from  
242 symptom onset to blood testing should be considered when physicians devise patients' treatment  
243 strategies.

244 In this study, BMI, age, and comorbidities were also analyzed in a multivariate regression  
245 model because they are well-known prognostic factors for COVID-19. The US Food and Drug  
246 Administration published criteria for the use of monoclonal antibodies to treat or prevent SARS-  
247 CoV-2 in consideration of risk factors including older age ( $\geq 65$  years), obesity (BMI  $> 25$  kg/m<sup>2</sup>  
248 in adults), pregnancy, and comorbidities such as chronic kidney disease, diabetes, and chronic  
249 lung disease (US Food and Drug Administration., 2021). BMI  $> 25$  kg/m<sup>2</sup> was similar to our  
250 cutoff of 25.2 kg/m<sup>2</sup>, but the number the cases was limited in our analysis. However, our analysis  
251 assessed all comorbidities collectively because we did not have sufficient numbers of  
252 participants to analyze comorbidities separately. The criteria of the Japanese Ministry of Health,  
253 Labor and Welfare indicated that patients younger than 50 years are eligible for monoclonal  
254 antibody therapy as high-risk patients (Japanese Ministry of Health, Labor and Welfare., 2021).  
255 Our age cutoff of 52 years was similar to these criteria.

256 Regarding study limitations, the number of cases was limited, and this study was  
257 performed retrospectively at a single hospital. Only some patients underwent blood testing at  
258 their visit based on the judgment of the physicians. Only 4.93% of patients received SARS-CoV-  
259 2 vaccines in this study, and the cutoffs might differ according to the receipt of vaccination.  
260 Ferritin and d-dimer levels also significantly differed between patients who did and did not  
261 receive oxygen therapy; however, the physicians did not measure these parameters in 14.7% of  
262 patients. Because all patients were ethnically Japanese, the results should be verified in other  
263 populations. Further studies are needed to confirm our findings.

264  
265  
266  
267

## 268 **Conclusions**

269 This study suggests that CRP  $\geq$  36 mg/L, and LDH  $\geq$  267 U/L are independent risk  
270 factors for oxygen therapy. Further studies concerning biomarkers will help physicians during  
271 the management of COVID-19.

## 272 **Supporting information**

273 **S1 Table. Characteristics of 282 outpatients who visited our hospital during the study**  
274 **period**

275 **S2 Table. Comorbidities of 142 patients who underwent blood testing**

## 276 **Acknowledgements**

277  
278 The authors thank all the participating physicians and other medical staffs for their care  
279 of patients with COVID-19.

280 COVID-19 medical team: Ai Nakamura, Akihito Tampo, Akiko Irie, Akito Uehara, Hidemitsu  
281 Sakagami, Kae Takahashi, Kazuki Yamada, Masahide Nakajima, Seisuke Saito, Shin Kukita,  
282 Shohei Kuroda, Roku Sato, Yuji Naito, Yuuki Nagasima

## 283 **References**

284  
285 Tabassum T, Rahman A, Araf Y, Ullah MA, Hosen MJ. Prospective selected biomarkers in  
286 COVID-19 diagnosis and treatment. *Biomark Med.* 2021;15: 1435-1449. doi:

287 <http://doi.org/10.2217/bmm-2021-0038> PMID: 34538093

288 Yamada G, Hayakawa K, Matsunaga N, Terada M, Suzuki S, Asai Y, Otsu H, Toyada A,  
289 Kitajima K, Tsuzuki S. Predicting respiratory failure for COVID-19 patients in Japan: a simple  
290 clinical score for evaluating the need for hospitalisation. *Epidemiol Infect.* 2021;149: e175(19).

291 doi: <https://doi.org/10.1017/S0950268821001837>

292 Vahey GM, McDonald E, Marshall K, Martin SW, Chun H, Herlihy R, Tate JE, Kawasaki B,  
293 Midgley CM, Alden N, Killerby ME, Staples JE, Colorado Investigation Team. Risk factors for  
294 hospitalization among persons with COVID-19-Colorado. *PLoS One.* 2021;16: e0256917. doi:

295 <https://doi.org/10.1371/journal.pone.0256917> PMID: 34473791

296 Ayanian S, Reyes J, Lynn L, Teufel K. The association between biomarkers and clinical  
297 outcomes in novel coronavirus pneumonia in a US cohort. *Biomark Med.* 2020;14: 1091-1097.

298 doi: <https://doi.org/10.2217/bmm-2020-0309>. PMID: 32677844

299 Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, Maharjan A, Gautam R.  
300 D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission  
301 and its role in predicting disease outcome in hospitalized patients with COVID-19. *PLoS One.*

302 2021;16: e0256744. doi: <https://doi.org/10.1371/journal.pone.0256744>. PMID: 34437642

303 Li C, Ye J, Chen Q, Hu W, Wang L, Fan Y, Lu Z, Chen J, Chen Z, Chen S, Tong J, Xiao W,  
304 Mei J, Lu H. Elevated lactate dehydrogenase (LDH) level as an independent risk factor for the  
305 severity and mortality of COVID-19. *Aging.* 2020;12: 15670-15681. doi:

306 <https://doi.org/10.18632/aging.103770>. PMID: 32805722

- 308 Rahman MA, Shanjana Y, Tushar MI, Mahmud T, Rahman GMS, Milan ZH, Sultana T,  
309 Chowdhury AMLH, Bhuiyan MA, Islam MR, Reza HM. Hematological abnormalities and  
310 comorbidities are associated with COVID-19 severity among hospitalized patients: Experience  
311 from Bangladesh. *PLoS One*. 2021;16: e0255379. doi:  
312 <https://doi.org/10.1371/journal.pone.0255379>. PMID: 34314447
- 313 Kilercik M, Demirelce Ö, Serdar MA, Mikailova P, Serteser M. A new haematocytometric  
314 index: Predicting severity and mortality risk value in COVID-19 patients. *PLoS One*. 2021;16:  
315 e0254073. doi: <https://doi.org/10.1371/journal.pone.0254073>. PMID: 34351940
- 316 Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. *Int J*  
317 *Antimicrob Agents*. 2020;56: 106051. doi: <https://doi.org/10.1016/j.ijantimicag.2020.106051>.  
318 PMID: 32534186
- 319 Ni YN, Wang T, Liang BM, Liang ZA. The independent factors associated with oxygen therapy  
320 in COVID-19 patients under 65 years old. *PLoS One*. 2021;16: e0245690. doi:  
321 <https://doi.org/10.1371/journal.pone.0245690>. PMID: 33481912
- 322 Kanda Y. Investigation of the freely available easy-to-use software 'EZ' for medical statistics.  
323 *Bone Marrow Transplant*. 2013;48: 452-458. doi: <https://doi.org/10.1038/bmt.2012.244>. PMID:  
324 23208313
- 325 Luan YY, Yin CH, Yao YM. Update advances on C-reactive protein in COVID-19 and other  
326 viral infections. *Front Immunol*. 2021;12: 720363. doi:  
327 <https://doi.org/10.3389/fimmu.2021.720363>. PMID: 34447386
- 328 Wang L. C-reactive protein levels in the early stage of COVID-19. *Med Mal Infect*. 2020;50:  
329 332-334. <https://doi.org/10.1016/j.medmal.2020.03.007>. PMID: 32243911
- 330 Azar MM, Shin JJ, Kang I, Landry M. Diagnosis of SARS-CoV-2 infection in the setting of the  
331 cytokine release syndrome. *Expert Rev Mol Diagn*. 2020;20: 1087-1097. doi:  
332 <https://doi.org/10.1080/14737159.2020.1830760>. PMID: 32990479
- 333 Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, Nuccetelli M, Vadacca GB,  
334 Guidetti D, Vercelli A, Magnacavallo A, Bernardini S, Terracciano C. Lactate dehydrogenase  
335 and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. *Clin Chim Acta*.  
336 2020;509: 135-138. doi:  
337 <https://doi.org/10.1016/j.cca.2020.06.012>. PMID: 32531257
- 338 Sadeghi-Haddad-Zavareh M, Bayani M, Shokri M, Ebrahimipour S, Babazadeh A, Mehraeen R,  
339 Moudi E, Rostami A, Barary M, Hosseini A, Bijani A, Javanian M. C-reactive protein as a  
340 prognostic indicator in COVID-19 patients. *Interdiscip Perspect Infect Dis*. 2021: 5557582. doi:  
341 <https://doi.org/10.1155/2021/5557582>. PMID: 33968148
- 342 Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, Quinn TJ, Vilches-Moraga A,  
343 Stechman MJ, Pearce L, Moug S, McCarthy K, Hewitt J, Carter B, COPE Study Collaborators.  
344 The role of C-reactive protein as a prognostic marker in COVID-19. *Int J Epidemiol*. 2021;50:  
345 420-429. doi: <https://doi.org/10.1093/ije/dyab012>. PMID: 33683344

346 Sepulveda JL. Challenges in routine clinical chemistry analysis: proteins and enzymes. In:  
347 Accurate results in the clinical laboratory 2019. Pp. 141-163. doi: [https://doi.org/10.1016/B978-](https://doi.org/10.1016/B978-0-12-813776-5.00010-8)  
348 [0-12-813776-5.00010-8](https://doi.org/10.1016/B978-0-12-813776-5.00010-8)

349 Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang C,  
350 Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F, Lisanti MP. Ketones and lactate  
351 increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in  
352 breast cancer: achieving personalized medicine via Metabolo-Genomics. *Cell Cycle*. 2011;10:  
353 1271-1286. doi: <https://doi.org/10.4161/cc.10.8.15330>. PMID: 21512313

354 US Food and Drug Administration. Fact Sheet for Health Care Providers: Emergency Use  
355 Authorization (EUA) of REGEN-COV (Casirivimab with Imdevimab). [Cited 2021 November  
356 16]. Available from: <https://www.fda.gov/media/145611/download>

357 Japanese Ministry of Health, Labour and Welfare. Shingata Korona Uirus Kansensho no tebiki  
358 dai 6 han. [Cited 2021 November 16] Available from:  
359 <https://www.mhlw.go.jp/content/000851082.pdf> (Japanese)  
360